Brad oversees all of GoodCell’s scientific programs and technologies. Prior to joining GoodCell, Brad was the Chief Technology Officer for ReproCELL, a multinational stem cell company focused on developing novel stem cell technologies and therapies.
Brad’s work for as a founding scientist and director of research for RepreCELL helped to develop groundbreaking RNA-mediated cellular reprogramming technologies, as well as applications for the generation of induced pluripotent stem cells from clinically accessible samples such as human skin, blood, and urine.
Brad has both published and presented this work internationally. He is a member of the International Society of Stem Cell Research (ISSCR), also serving on the Industry Committee since 2016. Prior to joining the field of stem cell research, Brad led research teams at RheoGene and Upstate Biotech (which was later acquired by Millipore), focusing on developing novel discovery technologies such as orthogonal, inducible mammalian gene expression switches, and RNAi screening platforms.
Brad holds an MS in biotechnology from the University of Tennessee—Knoxville, as well as a BS in biology from James Madison University.
Professor of Stem Cell and Regenerative Biology, Harvard University. Principal Investigator, Harvard Stem Cell Institute. Director, Stem Cell Biology, Stanley Center for Psychiatric Research at the Broad Institute.